Author

G. Migneco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

C. S. McKimmie· 2 shared F. Del Galdo· 2 shared R. L. Ross· 2 shared A. Antanaviciute· 1 shared A. Carriero· 1 shared B. Caballero-Ruiz· 1 shared C. Antinozzi· 1 shared C. Corinaldesi· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. S. McKimmie

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Beta secretase BACE1 drives fibroblasts activation in Systemic Sclerosis through the APP/Beta-catenin/Notch signalling axis

C. W. Wasson, E. De Lorenzis, E. M. Clavane, R. L. Ross, K. A. Walker, B. Caballero-Ruiz, C. Antinozzi, R. Wells, G. Migneco, J. M. Y. Brown, N. A. Riobo-Del Galdo, L. Di Luigi, C. S. McKimmie, F. Del Galdo, P. J. Meakin

This study shows BACE1 drives fibroblast activation in systemic sclerosis via the APP/Beta-catenin/Notch axis and identifies BACE1 as a potential therapeutic target.

bioRxiv · Dec 22, 2022Immunology

Targeting BDCA2 suppresses Plasmacytoid dendritic cell dependent interferon response and tissue fibrosis

R. L. Ross, C. Corinaldesi, G. Migneco, I. Carr, A. Antanaviciute, A. Carriero, C. Wasson, I. Georgiou, J. H. W. Distler, S. Holmes, Y. M. El-Sherbiny, C. S. McKimmie, F. Del Galdo

This study shows that targeting BDCA2 reduces pDC-driven interferon responses and fibrosis in preclinical models of skin inflammation.

bioRxiv · Jan 30, 2020 · PreprintImmunology